Coherus Oncology (CHRS) Change in Accured Expenses (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Change in Accured Expenses data on file, last reported at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 13.95% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at -$8.0 million (up 87.81% YoY), and the FY2025 full-year result was -$9.2 million, up 83.83% from the prior year.
• Change in Accured Expenses slipped to -$7.2 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $16.5 million in Q3 2023 to a low of -$55.8 million in Q4 2024.
• A 5-year average of -$4.6 million and a median of -$3.2 million in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 116.73% in 2023 and tumbled 1223.48% in 2025, its largest moves.
• Tracing CHRS's Change in Accured Expenses over 5 years: stood at $1.8 million in 2022, then plunged by 792.96% to -$12.6 million in 2023, then plunged by 343.22% to -$55.8 million in 2024, then surged by 107.95% to $4.4 million in 2025, then sank by 261.46% to -$7.2 million in 2026.
• Business Quant data shows CHRS's Change in Accured Expenses at -$7.2 million in Q1 2026, $4.4 million in Q4 2025, and $1.3 million in Q3 2025.